CJC-1295 With DAC 10mg

CJC-1295 With DAC 10mg Research Peptide UK

CJC-1295 With DAC 10mg is a synthetic analogue of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) designed to enable binding to circulating serum albumin. This albumin-binding property is the defining feature of the DAC modification and produces substantially prolonged pharmacokinetics compared with shorter-acting non-DAC GHRH analogues. In the published pharmacokinetic study by Teichman et al. (2006), CJC-1295 had an estimated half-life of approximately 5.8–8.1 days. This product is supplied strictly for laboratory research use.

Like other GHRH analogues, CJC-1295 With DAC acts as a selective agonist at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, initiating the cAMP/PKA signalling cascade associated with GH secretion in published research models. This extended pharmacokinetic profile is the defining research characteristic that makes it the most widely studied long-acting GHRH analogue in combined GHRH and GHRP research protocols.

CJC-1295 With DAC 10mg is most commonly studied alongside Ipamorelin 5mg or Ipamorelin 10mg. These two compounds target mechanistically distinct receptors: CJC-1295 with DAC targets GHRHR, while ipamorelin targets GHS-R1a (the ghrelin receptor). This receptor-level distinction allows them to function as independent variables in the same experimental protocol, producing synergistic GH pathway stimulation in published research models.

For researchers comparing GHRH analogue structures, this compound can be studied alongside CJC-1295 Without DAC 10mg (shorter-acting non-DAC analogue), Sermorelin 2mg (native sequence, shortest half-life), and Tesamorelin 5mg (full 44-amino acid GHRH sequence). Full mechanism and combined protocol data are available in the CJC-1295 With DAC research guide on the Ascend Peptides UK blog.

All CJC-1295 With DAC 10mg batches are independently tested by Janoshik. HPLC purity is confirmed at greater than or equal to 98%, with LC-MS molecular identity confirmed. The full Certificate of Analysis is available for independent verification.

For laboratory handling purposes, the lyophilised material may be reconstituted using bacteriostatic water or another suitable buffered aqueous solution, depending on analytical protocol requirements. Store lyophilised material at -20°C and avoid repeated freeze-thaw cycles.

WADA Status: Prohibited at all times under WADA and UKAD regulations.

DISCLAIMER: For in-vitro laboratory research only. Not for human consumption. Not an MHRA-licensed medicine.